Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

Humana (HUM) Q1 Earnings May Disappoint: Stock To Suffer?

Published 05/02/2016, 08:51 AM
Updated 07/09/2023, 06:31 AM

Humana Inc. (NYSE:HUM) is set to report first-quarter 2016 results on May 4, before the market opens. Last quarter, the company posted a negative earnings surprise of 0.68%. Let’s see how things are shaping up for this announcement.

Factors to be Considered this Quarter

Humana has likely witnessed an increase in operating expenses owing to higher benefit expenses as well as depreciation and amortization expenses.

Moreover, the company is expected to have experienced weakness in Group Medicare Advantage business in the first quarter. This is likely to adversely impact earnings and result in a fall in net membership.

However, Humana’s Medicare Part D Prescription Drug Plan (PDP) – part of its Medicare business – has likely displayed net membership growth in the to-be-reported quarter.

Notably, Humana is set to be acquired by Aetna Inc. (NYSE:AET) to form a combined company by the second half of 2016.

With respect to the surprise trend, the company delivered positive surprises in two of the last four quarters, with a negative beat of 0.11%.

Earnings Whispers

Our proven model does not conclusively show that Humana is likely to beat on earnings this quarter. This is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for this to happen. That is not the case here as you will see below.

Zacks ESP: Humana has an Earnings ESP of +0.55%. This is because the Most Accurate estimate is pegged at $1.82, while the Zacks Consensus Estimate stands at $1.81.

Zacks Rank: Humana carries a Zacks Rank #4 (Sell).

We caution against Sell-rated stocks (Zacks Rank #4 or 5) going into the earnings announcement, especially when the company is seeing negative estimate revisions.

Currently, the stock is trading at $177.07. We expect the release to lead to stock movement.

Stocks to Consider

Here are some companies from the medical sector that you may want to consider as these have the right combination of elements to post an earnings beat this quarter:

Aceto Corp. (NASDAQ:ACET) has an Earnings ESP of +5.26% and a Zacks Rank #3. The company is set to report first-quarter earnings on May 5.

Becton, Dickinson and Company (NYSE:BDX) has an Earnings ESP of +1.99% and a Zacks Rank #2. The company is slated to report first-quarter earnings on May 5.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .


ACETO CORP (ACET): Free Stock Analysis Report

AETNA INC-NEW (AET): Free Stock Analysis Report

HUMANA INC NEW (HUM): Free Stock Analysis Report

BECTON DICKINSO (BDX): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.